Table 5.

Influence of different combined oral contraceptive formulations in the anthropometric parameters of polycystic ovary syndrome

COC formulation	Number of studies	Before Md (1st – 3rd)	After Md (1st – 3rd)	∆	p*
BW
EE 35 μg / CPA 2 mg	02	69.6 (67.7–80.2)	69.8 (67.1–72.3)	+0.2	0.754
EE 30 μg / DRSP 3 mg	04	63.5 (60.1–66.2)	63.0 (61.8–65.1)	−0.5	0.465
EE 30 μg / CMA 2 mg	03	57.5 (55.9–59.7)	58.1 (56.7–61.3)	+0.4	0.653
EE 30 μg / DSG 75–150 μg	02	67.0 (66.1–67.9)	68.2 (67.5–70.1)	+1.2	0.900
BMI (kg/m2)
EE 35 μg / CPA 2 mg	13	24.0 (22.6–27.3)	23.1 (22.1–26.9)	−0.9	0.151
EE 30 μg / DRSP 3 mg	17	23.4 (22.2–26.4)	24.5 (22.7–26.3)	+1.1	0.924
EE 30 μg / CMA 2 mg	05	22.5 (22.2–23.3)	22.7 (22.5–23.4)	+0.2	0.138
EE 30 μg / DSG 75–150 μg	07	26.7 (24.4–30.1)	27.2 (23.8–29.2)	+0.5	0.262
WC (cm)
EE 30 μg / DRSP 3 mg	03	76.7 (74.0–79.4)	77.6 (75.4–79.2)	+0.9	0.810
EE 30 μg / CMA 2 μg	02	78.3 (78.0–78.7)	72.2 (77.0–77.4)	−1.1	0.089
EE 30 μg / NGM 180–250 μg	03	80.3 (63.3–97.3)	79.7 (63.7–95.7)	−0.6	0.179
WHR
EE 35 μg / CPA 2 mg	07	0.80 (0.74–0.91)	0.79 (0.74–0.88)	−0.01	0.179
EE 30 μg / DRSP 3 mg	12	0.78 (0.76–0.81)	0.75 (0.74–0.81)	−0.03	0.241
EE 30 μg / CMA 2 mg	02	0.73 (0.51–0.095)	0.78 (0.75–0.81)	−0.05	0.317
EE 30 μg / DSG 75–150 μg	04	0.81 (0.75–0.82)	0.80 (0.75–0.82)	−0.01	0.654
EE 30 μg / NGM 180–250 μg	02	0.80 (0.74–0.86)	0.78 (0.75–0.81)	−0.02	0.317
FM (kg)
EE 30 μg / DRSP 3 mg	03	21.0 (19.20–22.0)	22.9 (20.9–24.8)	+1.9	0.108

COC combined oral contraceptive, Md (1st – 3rd) median, first and third quartiles, BW body weight, BMI body mass index, WC waist circumference, WHR waist-hip ratio, FM fat mass, EE ethinylestradiol, CPA cyproterone acetate, DRSP drospirenone, CMA chlormadinone acetate, DSG desogestrel, NGM norgestimate

p* Wilcoxon signed- ranks test